Cognitive-behavioral treatment with behavioral activation for smoking cessation: Randomized controlled trial
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10347/21033
Files in this item
Metadata of this item
Title: | Cognitive-behavioral treatment with behavioral activation for smoking cessation: Randomized controlled trial |
Author: | Martínez Vispo, Carmela Rodríguez Cano, Rubén Agustín López Durán, Ana Senra Rivera, Carmen Fernández del Río, Elena Becoña Iglesias, Elisardo |
Affiliation: | Universidade de Santiago de Compostela. Departamento de Psicoloxía Clínica e Psicobioloxía |
Date of Issue: | 2019 |
Publisher: | PLOS |
Citation: | Martínez-Vispo C, Rodríguez-Cano R, López-Durán A, Senra C, Fernández del Río E, Becoña E (2019) Cognitive-behavioral treatment with behavioral activation for smoking cessation: Randomized controlled trial. PLoS ONE 14(4): e0214252. https://doi.org/10.1371/journal.pone.0214252 |
Abstract: | Introduction Behavioral Activation is a behavioral-based treatment that has been proposed as suitable for smoking cessation, as it simultaneously addresses reinforcement-related variables and also mood management. The aim of this study was to compare the effects of a cognitive-behavioral smoking cessation treatment with components of behavioral activation (SCBSCT-BA) with a standard cognitive-behavioral treatment (SCBSCT), and a wait-list control group (WL). Method The sample was comprised of 275 adults smokers (61.4% females, mean age = 45.36, SD = 10.96). After baseline assessment sessions, participants were randomized (ratio: 2.2.1.) to SCBSCT-BA, SCBSCT, or WL. Active groups received 8 weekly 1-hour face-to-face group sessions. Biochemically verified smoking abstinence and depressive symptoms were assessed at the end of treatment, and at 3-, 6-, and 12-month follow-ups. Results Significant treatment effects in 7-dayspoint prevalence abstinence rates were found for both active groups at the end of treatment. Abstinence rates at 12-months follow-up were 30% for SCBSCT-BA, and 18% for SCBSCT. Using Multiple Imputation for missing data, regression analysis showed significantly greater ORs for the SCBSCT-BA condition (vs. SCBSCT) at the end of treatment and at 3-months follow-up. At 6-, and 12-months follow-ups, ORs for the SCBSCT-BA condition, although greater, did not reach statistical significance. Multilevel analysis showed that abstinence was related to reductions in depressive symptoms. Conclusions SCBSCT-BA obtained positive results at short and medium term. Participants who quit smoking experienced a significant reduction in depressive symptoms. Findings support the benefit of adding BA to a cognitive-behavioral smoking cessation treatment |
Publisher version: | https://doi.org/10.1371/journal.pone.0214252 |
URI: | http://hdl.handle.net/10347/21033 |
DOI: | 10.1371/journal.pone.0214252 |
E-ISSN: | 1932-6203 |
Rights: | © 2019 Martínez-Vispo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License |
Collections
-
- Tratapsicolóxico-Artigos [65]
- PCP-Artigos [260]